NCT00000745View on ClinicalTrials.gov

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 1991

Conditions

HIV Infections

Interventions

BIOLOGICAL

Hepatitis B Vaccine (Recombinant)

BIOLOGICAL

gp160 Vaccine (MicroGeneSys)

Trial Locations (2)

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

Unknown

JHU AVEG, Pittsburgh

All Listed Sponsors

collaborator

Protein Sciences Corporation

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000745 - A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160 | Biotech Hunter | Biotech Hunter